Response rate of the third and fourth doses of the BNT162b2 vaccine administered to cancer patients undergoing active anti-neoplastic treatmentsAgbarya, Abed (Avtor) Sarel, Ina (Avtor) Ziv-Baran, Tomer (Avtor) Schwartz, Orna (Avtor) Shechtman, Yelena (Avtor) Kozlener, Ella (Avtor) Khoury, Rasha (Avtor) Ahmad, Mohammad Sheikh (Avtor) Saiegh, Leonard (Avtor) Swaid, Forat (Avtor) Asala Abu, Ahmad (Avtor) Janžič, Urška (Avtor) Brenner, Ronen (Avtor) SARS-CoV-2BNT162b2 vaccinecancer patientsanti-neoplastic treatmentchemotherapyantibodiesimmunogenicityCOVID-19immunocompromiseMDPI AG, 2013- 20232026-02-25 09:27:44Neznano27796UDK: 615ISSN pri članku: 2079-9721DOI: 10.3390/diseases11040128COBISS_ID: 168100867Diseasessl© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).